Truist Securities Reiterates Buy on PTC Therapeutics, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Barry Jonas has reiterated a 'Buy' rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a price target of $45.
September 19, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PTC Therapeutics has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $45.
The reiterated 'Buy' rating from Truist Securities indicates a positive outlook for PTC Therapeutics. The maintained price target of $45 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100